We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Human CRP-Levels Compared Using Point-of-Care Methods

By LabMedica International staff writers
Posted on 08 Oct 2019
Due to the rapid increase of the C-reactive protein (CRP) concentration in the event of an inflammatory disease, CRP is regarded as one of the most important acute phase proteins. More...
Inflammation and CRP play an important role in operations, trauma, mental stress, myocardial infarction and neoplastic diseases.

The use of point-of-care (POC) methods and the measurements of CRP as a diagnostic marker have both increased over the past years. This has led to an increase in POC-methods analyzing CRP. High CRP levels are often seen as an indication for the proscribing of antibiotics. The quality of POC-systems compared to routine diagnostic measurements for the analysis of CRP is thereby of major importance, since many small practices will use POC-methods.

Biomedical scientists from the Salzburg University of Applied Sciences (Puch bei Hallein, Austria) compared POC and classical clinical chemistry methods, using 199 anonymized patient samples (104 male and 95 female patients aged from 31 to 96 years). The blood samples were selected based on a CRP concentration of more than 100 mg/L as measured by the Architect ci8200SR.

Comparisons were then made with ABX Micros CRP 200 (Horiba, Kyoto, Japan) and the i-CHROMA system. The CRP-levels on the Architect ci8200 were detected using serum samples and the method is based on a turbidimetric assay. EDTA-whole blood was used for the test procedure with the i-CHROMA and ABX. The ABX also works with a turbidimetric assay system and the i-CHROMA is based on a fluorescence sandwich immunoassay. The values from the i-CHROMA were used corrected for the hematocrit values.

The scientists reported that the results of the Architect ci8200 and the ABX showed significant differences when compared to the results of the i-CHROMA with hematocrit corrections. In addition, the values of the Architect ci8200 and the ABXs were also significantly different. Nevertheless, the most pronounced differences were seen when comparing the i-CHROMA with the Architect ci8200 with detected differences of up to 147.6 mg/L. Comparing the values of the i-CHROMA with the ABX resulted in differences of up to 92.7 mg/L. The lowest maximal difference of 39.4 mg/L is seen when comparing the results of the Architect ci8200 and the ABX.

The authors concluded that the measured CRP concentrations of the i-CHROMA strongly differ in the higher CRP concentration range when compared to the measurements performed on routine diagnostic equipment. The significantly reduced CRP measurements can strongly affect patient safety and result in wrong diagnostic measures. The study was published on September 19, 2019, in the journal Practical Laboratory Medicine.


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.